Although the EGFR T790M secondary mutation is recognized as the most common mechanism, MET amplification is another critical factor that accounts for 5–22% of the resistance cases in NSCLC patients treated with first-generation EGFR TKIs [15,28]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.